BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the LD Micro Invitational XII which is being held on June 7– 9, 2022, at the Four Seasons Westlake Village, California.
Management is scheduled to present on Tuesday, June 7, 2022, at 11:30 am PT / 2:30 pm ET. The presentation will be webcast live and available for replay at ldinv12.mysequire.com. Management will also be available for one-on-one meetings with qualified investors throughout the conference.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
PhillComm Global
This email address is being protected from spambots. You need JavaScript enabled to view it.
704.942.1557
Last Trade: | US$0.43 |
Daily Volume: | 0 |
Market Cap: | US$5.480M |
August 15, 2024 April 03, 2024 February 08, 2024 January 09, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB